The review describes L. aspera as an annual herb reaching 15 to 60 centimeters in height, distributed widely across tropical and subtropical Asia, including India, Bangladesh, Nepal, Malaysia, and Mauritius. Its taxonomic classification places it in the Lamiaceae family alongside mint and basil, and its vernacular names across Indian languages reflect deep cultural familiarity. The plant blooms white, sessile, zygomorphic flowers from August to September, and every part, from roots to seeds, has found a place in traditional healing. In Ayurveda and Siddha medicine, the whole plant is used as a carminative, antipyretic, antiseptic, anti-inflammatory, and anti-snake venom agent, treating conditions ranging from jaundice and dyspepsia to rheumatism and respiratory ailments.

What gives the plant its versatility is an unusually rich phytochemical inventory. The review identifies roughly sixty chemical compounds spanning multiple structural classes, including flavonoids, alkaloids, terpenoids, glycosides, sterols, phenolic compounds, and fatty acids. Notable constituents include the triterpenoids ursolic acid and oleanolic acid, the diterpenes leucasperones A and B and leucasperols A and B, isopimarane glycosides known as leucasperosides A, B, and C, and the oleanane-type triterpenoid lactone leucolactone isolated from the roots. Seed oil contains linoleic, oleic, palmitic, stearic, and linolenic acids, while leaf volatiles are dominated by alpha-farnesene, alpha-thujene, and menthol. Lignans such as nectandrin B and macelignan, along with long-chain aliphatic ketones and alcohols, round out a chemical repertoire that rivals many cultivated medicinal species.

The pharmacological evidence assembled by the authors is striking in its breadth. Antimicrobial studies show that dichloromethane leaf extracts inhibit pathogens including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans at minimum inhibitory concentrations between 75 and 425 micrograms per milliliter, while methanolic whole-plant extracts, rich in flavonoids and phenolics, produce broad inhibition zones against both Gram-positive and Gram-negative bacteria. Antioxidant assays reveal that leaf flavonoids scavenge DPPH radicals with an IC50 of just 9.25 micrograms per milliliter, outperforming the reference compound gallic acid at equivalent doses. Perhaps most intriguingly, recent work has used the plant’s phytochemicals as reducing and stabilizing agents to biosynthesize chitosan-zinc oxide nanocomposites, which achieved up to 88.19 percent ABTS radical scavenging, a result attributed to synergistic interactions between the nanoparticle surfaces, chitosan functional groups, and the plant’s phenolic compounds.

Anti-inflammatory findings are similarly compelling. Extracts of the whole plant reduced cytokine production in mouse macrophage cells by 24 to 39 percent, suppressing interleukin-1 beta, a key pro-inflammatory mediator, and aqueous leaf extracts inhibited heat-induced red blood cell membrane denaturation by 73.25 percent at 100 micrograms per milliliter, nearly matching the standard drug diclofenac. In diabetes models, aqueous leaf extracts lowered blood glucose in streptozotocin-induced diabetic rats to 98.35 milligrams per deciliter at 400 milligrams per kilogram, outperforming the reference drug glibenclamide in some comparisons, while methanolic extracts reduced serum glucose by up to 42.10 percent in glucose-loaded mice. Researchers attribute these effects partly to the substantial quantities of oleanolic and ursolic acid found throughout the genus.

The review also documents hepatoprotective activity across several liver injury models, with extracts protecting against damage induced by paracetamol, carbon tetrachloride, lead acetate, and d-galactosamine by normalizing liver enzymes, reducing lipid peroxidation, and elevating antioxidant defenses such as glutathione peroxidase and catalase. Cytotoxicity studies against breast cancer cell lines showed that flavonoid and alkaloid fractions inhibited MCF-7 cell growth with IC50 values of 247.56 and 236.45 micrograms per milliliter respectively, while dichloromethane and ethyl acetate extracts suppressed proliferation in triple-negative MDA-MB-231 cells at concentrations as low as 3 to 5 micrograms per milliliter, suggesting potential as a source of leads against aggressive cancers.

Beyond these headline activities, the plant demonstrated analgesic effects across six pain models in mice, with a 700 milligrams per kilogram dose reducing responses by up to 84.74 percent, alongside verified anthelmintic, antipyretic, anti-ulcer, anti-asthmatic, anti-psoriatic, and anti-obesity properties. One of the more striking findings concerns snakebite: a triterpenoid isolated from the methanolic extract, 1-hydroxytetratriacontane-4-one, showed potent antidote activity against spectacled cobra venom in mice, and chitosan-based nanoparticles loaded with the plant extract neutralized Indian cobra venom toxicity. As a larvicide, the isolated compound catechin killed mosquito larvae, and silver nanoparticles synthesized from leaf extracts showed strong activity against the dengue vector Aedes aegypti, positioning the weed as an inexpensive bioresource for vector control.

Safety data support the plant’s traditional standing. Acute and sub-acute toxicity studies conducted under OECD guidelines 423 and 425 found no lethality or adverse behavioral changes at doses up to 2,000 milligrams per kilogram across multiple extract types and animal models, establishing median lethal doses above that threshold. The plant has already entered commercial use in homeopathic preparations, notably L. aspera 30CH dilutions marketed for asthma, cough, jaundice, dysentery, and intermittent fevers, and mother tinctures valued for their antipyretic and antimicrobial qualities. Its nutraceutical profile, marked by favorable mineral content and negligible heavy metal contamination, further suggests applications in functional foods, while its essential oils show promise as eco-friendly biopesticides.

Yet the review’s authors are candid about the gaps that separate preclinical enthusiasm from clinical reality. Most pharmacological data derive from in vitro experiments and animal studies, human trials are scarce, and variations in plant parts, extraction methods, and experimental protocols complicate comparisons across studies. Chronic toxicity, reproductive safety, genotoxicity, pharmacokinetics, and herb-drug interactions remain essentially uncharacterized, and many studies use crude extracts without adequate phytochemical standardization. Overexploitation also threatens wild populations, prompting calls for tissue culture conservation, transgenic development, and metabolite enhancement. The authors argue that the path forward lies in isolating novel bioactive compounds, standardizing formulations, applying nanotechnology-based delivery systems, and ultimately conducting randomized clinical trials. If those steps succeed, a weed once dismissed from the margins of wastelands may yet earn a place in the modern pharmacopoeia.

Subject of Research: Phytochemistry, pharmacological activities, and clinical applications of the medicinal plant Leucas aspera

Article Title: A comprehensive review of the phytochemistry, pharmacological activities and clinical applications of Leucas aspera

Article References: Pathak, M., Gaba, V., & Joshi, B. C. (2026). A comprehensive review of the phytochemistry, pharmacological activities and clinical applications of Leucas aspera. Discover Chemistry, 3(1), Article 525. https://doi.org/10.1007/s44371-026-00971-4

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00971-4

Keywords: Leucas aspera, phytochemistry, pharmacological activities, Dronapushpi, Ayurveda, antimicrobial, anti-inflammatory, antidiabetic, hepatoprotective, snake venom, larvicidal, natural products

MDS, a condition marked by excessive fat accumulation and inflammation in the liver, progressively impairs hepatic function and can trigger cirrhosis or liver cancer. Traditional therapies have often fallen short, primarily due to the multifactorial nature of the disease’s pathogenesis. This has propelled researchers towards exploring systemic hormone pathways that regulate energy metabolism, insulin sensitivity, and inflammation. Central to this emerging therapeutic paradigm are hormones that originally mediate glucose homeostasis but show promising hepatoprotective effects beyond their classical roles.

Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), have garnered attention for their dual regulatory effects on metabolism and inflammation. These peptide hormones enhance insulin secretion, suppress glucagon release, and slow gastric emptying, all of which contribute to improved glycemic control. More intriguingly, their receptor agonists have shown a capacity not only to reduce hepatic steatosis but also to attenuate inflammatory and fibrotic markers within the liver. This positions incretin-based therapies as potent modulators capable of addressing multiple pathological axes of MDS.

FGF analogs represent another class of promising metabolic hormone agents. These proteins, especially FGF19 and FGF21, function as key regulators of lipid metabolism, energy expenditure, and insulin sensitivity. Synthetic analogs have been engineered to optimize receptor binding and extend half-life, enhancing their therapeutic viability. Preclinical and early clinical data reveal that FGF analogs can reduce liver fat accumulation, resolve inflammation, and disrupt the fibrogenic cascade, which could translate into meaningful disease modification in patients with MDS.

An essential aspect of advancing these hormonal therapeutics lies in optimizing liver-targeting strategies. The liver’s unique microenvironment and cell populations offer specific opportunities to enhance drug delivery and efficacy while minimizing systemic side effects. Innovative approaches such as conjugation with molecules that exploit hepatic transporter systems, nanoparticle encapsulation, and prodrug designs are under active development. These strategies ensure that therapeutic concentrations of peptides or analogs are achieved specifically in hepatic tissues, maximizing local benefit and safety.

The intricate mechanisms underlying the therapeutic effects of incretin-based drugs illustrate their multifaceted influence on hepatic metabolism. GLP-1 receptor agonists, for instance, promote mitochondrial biogenesis within hepatocytes, improving oxidative capacity and reducing lipid accumulation. Additionally, their anti-inflammatory properties mitigate Kupffer cell activation and necroinflammatory processes, pivotal contributors to MDS progression. Such pleiotropic effects signify a paradigm shift from symptomatic treatment to correction of underlying metabolic disturbances.

FGF analog therapeutics exert their impact through complex signaling cascades involving FGF receptors coupled with coreceptors like β-Klotho. By modulating these pathways, they orchestrate systemic improvements including enhanced fatty acid oxidation, reduced de novo lipogenesis, and increased insulin sensitivity, all converging to alleviate hepatic steatosis. Furthermore, FGF21 analogs suppress proinflammatory cytokine secretion and stabilize hepatic stellate cell activation, which drives fibrosis. These molecular insights reinforce their capacity to modify disease trajectory fundamentally.

Clinical trial data, while still emerging, provides encouraging evidence supporting safety and efficacy of these treatments. Recent phase II studies reveal significant reductions in liver fat content measured by imaging modalities and biomarkers, alongside improvements in metabolic parameters such as HbA1c and lipid profiles. The tolerability profile remains favorable, with gastrointestinal symptoms constituting the most common adverse events, typically mild to moderate in severity. These preliminary findings lay the groundwork for more expansive phase III trials aimed at regulatory approval.

Moreover, the combinatorial use of incretin-based drugs with FGF analogs is an area of intense investigation. Such combinations potentially leverage complementary mechanisms, amplifying metabolic and hepatic benefits. Synergistic effects could include enhanced glucose regulation, superior anti-inflammatory activity, and more robust antifibrotic response. This integrated approach reflects an advanced understanding of MDS’s multifaceted nature, harnessing therapeutic synergies to optimize outcomes.

Underlying all therapeutic advances is a growing body of knowledge about the pathophysiological network orchestrating MDS. This informs the strategic design of hormone mimetics and analogs capable of intercepting disease progression at multiple junctures. Importantly, recognizing the heterogeneity within patient populations guides the application of personalized medicine, tailoring hormone-based interventions to individual metabolic phenotypes and disease stages.

What distinguishes this emerging class of metabolic hormone therapeutics is their potential to fill a critical gap in current treatment standards, which largely rely on lifestyle modification and limited pharmacological options addressing only singular aspects of the disease. By targeting key metabolic regulatory nodes, these agents promise a holistic approach capable of reversing steatosis, curbing inflammation, and halting or even reversing fibrosis, thereby preventing progression to cirrhosis and liver failure.

Future research directions will likely involve refining delivery platforms to enhance hepatic targeting, extending peptide half-lives, and minimizing immunogenicity. Parallel efforts to identify robust biomarkers for early detection and for monitoring treatment response are crucial. Additionally, long-term outcome studies assessing impacts on liver-related morbidity and mortality will validate the clinical utility of these novel therapies, shaping future guidelines for metabolic liver disease management.

In conclusion, the integration of incretin-based drugs, FGF analogs, and advanced liver-targeting strategies delineates a transformative horizon in the treatment of metabolic dysfunction-associated steatohepatitis. This innovative approach exemplifies how understanding and harnessing hormone signaling pathways can lead to therapeutics that not only manage symptoms but actively reverse disease pathology. As research progresses, these metabolic hormone therapeutics hold the promise to profoundly affect patient lives and redefine standards of care in hepatology and metabolic medicine.

Subject of Research: Metabolic hormone therapeutics targeting metabolic dysfunction-associated steatohepatitis (MDS).

Article Title: Emerging metabolic hormone therapeutics for metabolic dysfunction-associated steatohepatitis: incretin-based drugs, fibroblast growth factor analogs, and liver-targeting strategies.

Article References:
Han, S., Shin, J., Kim, J.C. et al. Emerging metabolic hormone therapeutics for metabolic dysfunction-associated steatohepatitis: incretin-based drugs, fibroblast growth factor analogs, and liver-targeting strategies. J. Pharm. Investig. (2026). https://doi.org/10.1007/s40005-026-00815-4

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s40005-026-00815-4